InThera Inc., a leading-edge Korean-based bioventure incorporated in 2016, aims to develop and deliver virus-like particle (VLP) vaccines against emerging/re-emerging viral infections.

Emerging viruses pose a major threat to humans and livestock with global public health and economic burdens. Vaccination remains the most effective means to reduce the threat, and yet, the conventional cell culture often fails to deliver sufficient vaccine dose in a timely manner. As an alternative to cell-culture based vaccine, virus-like particles (VLPs) are considered as a high priority vaccine strategy.

InThera established a novel technical platform for VLP design and bioprocessing modalities for efficient and cost-effective production. The endeavor will heighten the translation opportunity for unmet-need vaccines for global concern, as well as providing alternative means for the delivery of safer and more effective version of previously licensed vaccines.

After incorporation early 2016, InThera Inc, was certified as a venture company by Korean Government in Feb, 2018. Having established the affiliated research institute, the company has secured several Government funding for designer VLP vaccines. With norovirus and foot-and-mouth disease virus (FMDV) as top priorities, the company continues to expand target diseases in human and animals based on the global market need and national strategic plan for infectious diseases.

CEO
Deog-Young Choi, Ph.D.